Elaine Coustan-Smith

Coustan-Smith Elaine

  • Principal Research Scientist, Department of Paediatrics
Academic Qualifications
  • ASCP (QCYM), American Society for Clinical Pathology Board of Registry
  • Specialty in Immunology, Nottingham Trent University, United Kingdom
  • FIBMS, Specialty in Haematology, Sheffield Hallam University, United Kingdom
Research Interest(s)
  • Leukaemia Classification
  • Minimal Residual Disease
Recent Publications
  • 1. Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH. 2015 Dec. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood. 126(26):2896-9. doi: 10.1182/blood-2015-09-671131. 26527677.
  • 2. Ching-Hon Pui, Deqing Pei, Elaine Coustan-Smith, Sima Jeha, Cheng Cheng, W Paul Bowman, John T Sandlund, MD, Raul C Ribeiro, Jeffrey E Rubnitz, Hiroto Inaba, Deepa Bhojwani, Tanja A Gruber, Wing H Leung, James R Downing, William E Evans, Mary V Relling, Dario Campana. 2015 Apr. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology. 16(4):465-474. doi: 10.1016/S1470-2045(15)70082-3. 25800893.
  • 3. Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H. 2015 Jan. Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol. 168(1):94-101. doi: 10.1111/bjh.13107. 25164427.
  • 4. Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE. 2014 Dec. A revised definition of cure of childhood acute lymphoblastic leukemia. Leukemia. 28(12):2336-43. doi: 10.1038/leu.2014.142. 24781017.
  • 5. Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, Sandlund JT, Jeha S, Easton J, Becksfort J, Zhang J, Coustan-Smith E, Raimondi SC, Leung WH, Relling MV, Evans WE, Downing JR, Mullighan CG, Pui CH. 2014 Sep. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on levels of minimal residual disease. J Clin Oncol. 32(27):3012-20. doi: 10.1200/JCO.2014.55.4105. 25049327.